Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 17/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PKLR | P30613 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114544 | 0.89 | PKM (1.00) | PKMALDH1A1PKLR | |
| SCHEMBL2591579 | 0.89 | PKM (1.00) | PKMALDH1A1PKLR | |
| SCHEMBL2585274 | 0.84 | PKM (1.00) | PKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28927624 | 0.81 | PKM (0.73) | PKMALDH1A1 | |
| SCHEMBL2583932 | 0.80 | PKM (0.71) | PKMALDH1A1PKLRLMNASMN1; SMN2 | |
| SCHEMBL2591204 | 0.79 | PKM (1.00) | PKMALDH1A1PKLR | |
| SCHEMBL2592413 | 0.79 | PKM (1.00) | PKMALDH1A1PKLR | |
| SCHEMBL30114233 | 0.79 | ALDH1A1 (0.77) | PKMALDH1A1 | |
| SCHEMBL2587353 | 0.79 | ALDH1A1 (0.77) | PKMALDH1A1 | |
| SCHEMBL2588694 | 0.78 | PKM (1.00) | PKMALDH1A1PKLRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708267-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-20110105477-A1 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105477-A1 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | PREP, HPN, PEPD | PKM 2276/4885MAPK1 2579/4885ALDH1A1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.